Target FOXC1 in Pancreatic Cancer?
A team of Texas-based oncologists says their preclinical study results “demonstrate that IGF-1R and FOXC1 seem to positively regulate each other.”
Pancreatic Tumor Signal Blocks T-Cell Infiltration, Immunotherapy
“Tumor cell–intrinsic factors shape the tumor immune microenvironment and influence the outcome of immunotherapy,” the lead study author concluded.
Experts Weigh in on Planned FDA Drug Shortages Task Force
FDA, CMS, and Department of Veterans Affairs experts will be included. Dr. Robin Zon, a past chair of ASCO’s Government Relations Committee, said it is “critical” that the FDA work with providers and patients.
Survival Benefit From Immunotherapy With Modified Poliovirus in Recurrent Glioblastoma?
A noncontrolled phase I study in recurrent metastatic glioblastoma showed 3-year survival was five times higher in patients treated with intratumoral PVSRIPO.
Quiz: Understand USPSTF Recommendations for Preventing Skin Cancer
How well do you understand skin cancer risks? Test yourself with our latest quiz, and learn about USPSF recommendations for skin cancer prevention.
‘Highjack’ Autoimmunity to Enhance Efficacy of Immunotherapy?
Overexpression of IKZF1 facilitates immune attack on skin cancer and other solid tumors.
Quiz: Understand the Role of Adipose Tissue in Multiple Myeloma
Our latest quiz highlights the role of bone marrow adiposity in patients with multiple myeloma.
Splice Variant of MUC4 Promotes Pancreatic Cancer Progression
When MUC4/X-overexpressing pancreatic cancer cells were transplanted into mice, tumors grew aggressively, with significant metastasis to liver and peritoneum.
High-Dose PPI Plus Aspirin Reduced Esophageal Cancer Risk
Combination therapy with a high-dose proton pump inhibitor and aspirin reduced the risk of progression to esophageal cancer in patients with Barrett esophagus.
CDK12 Loss a Biomarker for Prostate Cancer Response to Immunotherapy?
DNA and RNA sequencing results suggest prostate cancer treatment “involving inhibition of CDK12 and immune checkpoint blockade,” a U Michigan team said.
Fewer Genetic Testing Referrals for Minorities With Ovarian Cancer
Following diagnosis, only one-third of black women in this retrospective study were referred to genetic counselors-and none actually received counseling.
Avelumab Plus Lorlatinib Active in ALK+ NSCLC
An avelumab combination therapy shows promise against ALK-driven lung cancers, but another was neither safe nor effective in non–ALK-driven cases.
Analysis Highlights Changes in 8th Edition AJCC Melanoma Staging System
“Now that effective adjuvant therapy has arrived in melanoma, accurate staging and patient selection to optimize a risk/benefit ratio is crucial,” emphasizes lead author Max Madu.
Improved OS With Dacomitinib vs Gefitinib in Selected EGFR+ NSCLC
Researchers in Hong Kong found dacomitinib was associated with longer OS than gefitinib in patients with advanced EGFR+ NSCLC.
Weekly Online Symptoms Survey Linked to Prolonged OS in Lung Cancer
Weekly patient symptom self-reports, filed using an online tool, allowed timely detection of lung cancer relapses and prolonged patient survival.
T-VEC Immunotherapy Shows Promising Early Activity in Melanoma
The genetically engineered oncolytic herpes simplex virus produced promising clinical responses in stage IIIB–IVM1a melanoma.
Steroids Diminish Survival Benefits From ICIs in Lung Cancer
Corticosteroid medications are associated with poorer outcomes of therapy with immune checkpoint inhibitors for patients with lung cancer.
Pembrolizumab Shows Antitumor Activity in Clear Cell RCC
Pembrolizumab monotherapy showed promising antitumor activity in clear cell RCC in the phase II KEYNOTE-427 trial.
Patients Report Better RCC Outcomes for Atezolizumab + Bevacizumab
Patients treated for RCC with atezolizumab plus bevacizumab reported fewer impacts to daily function and quality of life than those on sunitinib.
Ibrutinib/Rituximab Yields Prolonged PFS in Waldenström Macroglobulinemia
In the randomized phase III iNNOVATE trial, adding ibrutinib to rituximab significantly improved PFS in patients with Waldenström macroglobulinemia.
No OS Benefit From HIPEC in Colorectal Cancer
Overall, patients with mCRC and isolated peritoneal carcinomatosis did not benefit when hyperthermic intraperitoneal chemotherapy was added to surgery.
Ibrutinib Plus Venetoclax Shows Promising Activity Against CLL
In CAPTIVATE, first-line ibrutinib plus venetoclax yielded a high rate of undetectable residual disease, without new safety signals, in chronic lymphocytic leukemia.
Many With Metastatic Kidney Cancer Can Forego Surgery
For many patients diagnosed with metastatic renal cell carcinoma, sunitinib alone is not inferior to surgery followed by sunitinib.
Is Pembrolizumab Appropriate Before EGFR TKI Therapy in Lung Cancer?
Administering pembrolizumab before EGFR TKIs may be inappropriate for TKI-naive patients with EGFR-mutant NSCLC.
Women Can Safely Skip Chemotherapy for Some Early-Stage Breast Cancers
Tumor gene expression testing identifies women with certain early-stage breast cancers who can safely skip chemotherapy.
Pembrolizumab, Pemetrexed, and Carboplatin Improve Lung Cancer Survival
Adding pembrolizumab to pemetrexed and carboplatin for advanced nonsquamous NSCLC is associated with improved overall survival at 24 months.
Pegylated IL-10 Is Tolerable, Active in Metastatic RCC
Preliminary findings for pegilodecakin plus immune checkpoint inhibition suggest that the combination is tolerable and shows clinical activity.
Alectinib Outperforms Crizotinib in ALK+ Lung Cancer
Alectinib was generally better tolerated and associated with better outcomes vs crizotinib in ALK mutation–positive non–small-cell lung cancer.
Alectinib Plus Atezolizumab Is Safe in Patients With ALK+ Lung Cancer
Combining the ALK inhibitor with this immunotherapeutic agent had an acceptable safety profile and yielded an ORR of 85.7%, South Korean investigators reported.
Taselisib Modestly Delays Progression in ER+ Breast Cancer
The PI3K inhibitor taselisib offered less dramatic clinical benefits than anticipated, and with significant toxicities.